Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 1/20 | 0.81 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.71 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.64 |
| ▸ | BACE1 | P56817 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.53 |
| ▸ | CXCL8 | P10145 | 2/20 | 0.53 |
| ▸ | TNF | P01375 | 2/20 | 0.53 |
| ▸ | NOD2 | Q9HC29 | 2/20 | 0.53 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22844184 | 0.95 | CXCR4 (0.84) | CXCR4TLR8POLBNUDT1BACE1 | |
| SCHEMBL22844179 | 0.94 | CXCR4 (0.81) | CXCR4TLR8POLBNUDT1BACE1 | |
| SCHEMBL22844258 | 0.94 | CXCR4 (0.81) | CXCR4TLR8POLBNUDT1BACE1 | |
| SCHEMBL7164854 | 0.90 | CXCR4 (0.93) | CXCR4TLR8POLBHTTCYP1A2 | |
| SCHEMBL6196399 | 0.90 | CXCR4 (1.00) | CXCR4TLR8POLBHTTCYP1A2 | |
| SCHEMBL14447553 | 0.88 | CXCR4 (0.96) | CXCR4TLR8POLBHTTCYP1A2 | |
| SCHEMBL6197634 | 0.88 | CXCR4 (0.96) | CXCR4TLR8POLBHTTCYP1A2 | |
| SCHEMBL6199065 | 0.86 | CXCR4 (0.85) | CXCR4TLR8POLBHTTCYP1A2 | |
| SCHEMBL2343059 | 0.83 | TLR8 (1.00) | CXCR4TLR8POLBHTTCYP1A2 | |
| SCHEMBL1170110 | 0.82 | TLR8 (1.00) | CXCR4TLR8POLBHTTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180298026-A1 | Pyrazolo[1,5a]Pyrimidine Derivatives as IRAK4 Modulators | HOFFMANN-LA ROCHE INC. | 2018-10-18 | — | — | US | disclosed |
| US-10023589-B2 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | HOFFMANN-LA ROCHE INC. (US) | 2018-07-17 | — | — | US | disclosed |
| EP-3252054-A1 | PYRAZOLO[1,5A]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2017-12-06 | — | — | EP | disclosed |
| EP-2593457-B1 | PYRAZOLO[1,5A]PYRIMIDINE AND THIENO[3,2B]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | HOFFMANN LA ROCHE (CH) | 2017-08-23 | — | — | EP | disclosed |
| US-20160207936-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | HOFFMANN-LA ROCHE INC. | 2016-07-21 | — | — | US | disclosed |
| WO-2016077541-A1 | NOVEL ANTI-INFECTIVE COMPOUNDS AND METHODS USING SAME | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-05-19 | — | — | WO | disclosed |
| WO-2016077541-A1 | NOVEL ANTI-INFECTIVE COMPOUNDS AND METHODS USING SAME | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-05-19 | — | — | WO | disclosed |
| US-9255110-B2 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | ROCHE PALO ALTO LLC (US) | 2016-02-09 | — | — | US | disclosed |
| US-20140303149-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | HOFFMANN-LA ROCHE INC. (US) | 2014-10-09 | — | — | US | disclosed |
| WO-2010126922-A1 | BENZIMIDAZOLECARBOXAMIDES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC (US) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160207936-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | IRAK4, IRAK1, IRAK2 | CXCR4 252/4885TLR8 45/4885POLB 1848/4885 |
| US-20140303149-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | IRAK4, IRAK1, IRAK2 | CXCR4 252/4885TLR8 45/4885POLB 1848/4885 |
| US-10023589-B2 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | IRAK4, IRAK1, IRAK2 | CXCR4 252/4885TLR8 45/4885POLB 1848/4885 |
| US-20180298026-A1 | Pyrazolo[1,5a]Pyrimidine Derivatives as IRAK4 Modulators | IRAK4, IRAK1, IRAK2 | CXCR4 252/4885TLR8 45/4885POLB 1848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.